Thalidomide , ≥98% , 50-35-1

Synonym(s):
(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione;(±)-Thalidomide - CAS 50-35-1 - Calbiochem;(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione;(±)-Thalidomide

CAS NO.：50-35-1

Empirical Formula: C13H10N2O4

Molecular Weight: 258.23

MDL number: MFCD00153873

EINECS: 200-031-1

PRODUCT Properties

• Melting point: 269-271°C
• Boiling point: 401.48°C (rough estimate)
• Density: 1.2944 (rough estimate)
• refractive index: 1.5300 (estimate)
• storage temp.: Keep in dark place,Sealed in dry,Room Temperature
• solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.6 mg/mL
• form: White solid
• pka: 10.70±0.40(Predicted)
• color: white
• Water Solubility: <0.1 g/100 mL at 22 ºC
• λmax: 300nm(lit.)
• Merck: 14,9255
• Stability: Stable. Combustible. Incompatible with strong oxidizing agents.
• InChIKey: UEJJHQNACJXSKW-UHFFFAOYSA-N
• CAS DataBase Reference: 50-35-1(CAS DataBase Reference)
• NIST Chemistry Reference: Phthalimide, n-(2,6-dioxo-3-piperidyl)-(50-35-1)
• EPA Substance Registry System: Thalidomide (50-35-1)

Description and Uses

(±)-Thalidomide is an immunomodulatory compound with diverse biological activities, including anticancer, anti-inflammatory, and teratogenic properties. It prevents polymorphonuclear leukocyte (PMN) chemotaxis when used at concentrations of 1, 10, and 100 μg/ml. (±)-Thalidomide increases IL-2-induced proliferation and IFN-γ production in primary human T cells in vitro. It enhances natural killer (NK) cell-mediated cytotoxicity in MM.1S multiple myeloma cells. Thalidomide (4 mg/animal) reduces lung IL-6, TGF-β, VEGF, angiopoietin-1, angiopoietin-2, and collagen type Iα1 expression, inhibits pulmonary angiogenesis, and attenuates fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis. It induces apoptosis in primary human embryonic fibroblasts (EC₅₀ = 8.9 μM) and induces limb and eye defects in chicken embryos (EC₅₀ = 50 μg/kg egg weight). Formulations containing thalidomide have been used in the treatment of multiple myeloma and erythema nodosum leprosum (ENL) in non-pregnant individuals.

antiinfective (topical)

Safety

• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Hazard statements: H301-H312-H360D
• Precautionary statements: P201-P202-P264-P280-P301+P310-P302+P352+P312
• Hazard Codes: T
• Risk Statements: 46-61-21-25-62-22
• Safety Statements: 53-22-26-36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• RTECS: TI4375000
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 29337900
• Hazardous Substances Data: 50-35-1(Hazardous Substances Data)
• Toxicity: LD50 oral in mouse: 2gm/kg
• Limited Quantities: 5.0 L (1.3 gallons) (liquid) or 5.0 kg (11 lbs) (solid)
• Excepted Quantities: Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)